Bayer announced a clinical trial collaboration alliance with the University of Colorado Anschutz Medical Campus, UCHealth, and Children’s Hospital Colorado, marking the first time Bayer has structured a formal academic medical center partnership of this kind. The alliance covers multiple therapeutic areas — oncology, cardiovascular disease, chronic kidney disease, neurodegenerative disease, cell and gene therapy, women’s health, and ophthalmology — and is intended to accelerate trial execution, expand patient enrollment, and improve access to Bayer’s investigational therapies. Financial terms were not disclosed.

The arrangement is operational rather than asset-specific. Bayer contributes its drug development infrastructure and a pipeline of investigational therapies; the academic partners contribute clinical trial site capacity, patient populations, physician-scientists, and data science infrastructure. UCHealth University of Colorado Hospital has already been selected as a Phase III clinical trial site for an investigational cellular therapy for advanced Parkinson’s disease, the first concrete program identified under the alliance. Children’s Hospital Colorado, which draws pediatric patients from across the Rocky Mountain region, is also exploring additional pediatric trial opportunities with its physician-scientists.

Bayer is an active dealmaker in academic research collaboration, having structured a research collaboration with Vanderbilt University Medical Center in January 2026 — a five-year cardiovascular and kidney disease collaboration leveraging Vanderbilt’s BioVU genomic data platform — and with Tsinghua University in June 2025, extending a 16-year research partnership for a further three years across oncology, cardiovascular, renal, and immunology programs. The CU Anschutz deal is described as Bayer’s first academic medical center alliance specifically structured around clinical trial collaboration and execution, as distinct from earlier-stage drug discovery partnerships. CU Anschutz has separately demonstrated capacity to advance cell therapies through the clinic, having received US FDA clearance in April 2026 for a campus-built CD64-directed CAR T-cell therapy in acute myeloid leukemia — the first such IND clearance for a CAR T product developed entirely on a US academic campus.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/